Quintrio
Home

PHARMACEUTICAL PREPARATIONS

COMPASS Pathways Plc American Depository Shares

CMPS

Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.

Last trade $8.03
Day change -$0.245 (-2.96%)
Day range $7.82 – $8.41
Volume 1,968,967
Market cap $1.17B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.17B
Price / earnings
—
Price / book
8.25×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.94×

Profitability

Earnings per share
-$1.97
Return on assets
-53.91%
Return on equity
-197%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.36×
Current ratio
1.5×
Quick ratio
1.5×
Cash ratio
1.36×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$176.8M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CMPS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$32.98M$23.2M$16.42M$16.05M$13.21M$12.61M$18.74M$16.27M
Research and development$23.46M$29.18M$26.48M$29.91M$27.33M$30.33M$30.88M$32.14M
Total operating expenses$56.44M$52.37M$42.9M$45.95M$40.54M$42.93M$49.62M$48.41M
Operating income-$56.44M-$52.37M-$42.9M-$45.95M-$40.54M-$42.93M-$49.62M-$48.41M
Interest expense-$1.51M-$1.48M-$1.47M-$1.14M-$1.11M-$1.15M-$1.12M-$1.13M
Income before taxes-$10.94M-$253.46M$91.19M-$96.61M-$137.95M-$38.27M-$17.51M-$42.31M
Income taxes-$1.11M$331K-$11K-$2.73M-$230K$137K$354K$1.02M
Net income-$9.83M-$253.79M$91.2M-$93.88M-$137.72M-$38.4M-$17.86M-$43.33M
Net income attributable to common shareholders-$9.83M-$253.79M$77.64M-$93.88M-$137.72M-$38.4M-$17.86M-$43.33M
EBITDA-$56.44M-$52.37M-$42.9M-$45.95M-$40.52M-$42.78M-$49.58M-$48.36M
Basic earnings per share-$0.07-$1.88$0.71-$0.98-$1.44-$0.41-$0.20-$0.63
Diluted earnings per share-$0.31-$1.88-$0.30-$1.08-$1.44-$0.41-$0.24-$0.63

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Compass Pathways: 3 Key Takeaways for Long-Term Investors

Compass Pathways announced it will complete its New Drug Application submission for COMP360 within two weeks, positioning its synthetic psilocybin candidate for treatment-resistant depression. The company benefits from an established network of 8,500+ interventional psychiatry clinics, with 90% of surveyed psychiatrists willing to prescribe COMP360. With $444 million in cash reserves, the company is well-funded through 2028 and the planned 2027 commercial launch.

The Motley Fool

1 Reason Compass Pathways Is Worth a Second Look This Month

Compass Pathways is developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression. With positive Phase 3 trial results and an FDA Commissioner's National Priority Voucher, the company expects to complete its FDA application by end of 2026, potentially leading to approval in early 2027. Analysts project 95% upside from current $12 share price to average target of $23.75.

Investing.com

These 3 Psychedelic Stocks Activated After Trump’s Executive Order

Trump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with high upside targets, these remain speculative investments with substantial risks.

Investing.com

Wall Street Is Betting on More Than Marijuana

An executive order fast-tracking psychedelic medicines to market has bifurcated the alternative drug sector. Psychedelic stocks like Compass Pathways and Atai Beckley surged 40% and 20% respectively due to regulatory tailwinds and short squeezes, while mature cannabis operators like Curaleaf and Innovative Industrial Properties are now valued as stable, cash-generating businesses rather than speculative plays.

The Motley Fool

Why Compass Pathways Stock Rocketed 40% Today

Compass Pathways stock surged over 40% following a White House Executive Order aimed at accelerating approval of psychedelic drug treatments for mental health. The company's COMP360 synthetic psilocybin therapy has completed two positive phase 3 trials for treatment-resistant depression and is now on a faster regulatory track with the FDA.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.